494
Participants
Start Date
February 28, 2007
Primary Completion Date
June 30, 2009
Study Completion Date
June 30, 2009
exenatide twice daily (BID)
subcutaneous injection (5 mcg or 10 mcg), twice a day
premixed insulin aspart twice daily (BID)
subcutaneous injection (titrated appropriately), twice a day
Research Site, Bad Mergentheim
Research Site, Berlin
Research Site, Bosenheim
Research Site, Burghausen
Research Site, Datteln
Research Site, Dresden
Research Site, Essen
Research Site, Friedrichsthal
Research Site, Hildesheim
Research Site, Hirschhorn
Research Site, Hohenmölsen
Research Site, Jena
Research Site, Lehrte
Research Site, Leipzig
Research Site, Ludwigsburg
Research Site, Mannheim
Research Site, Marburg
Research Site, Marktheidenfeld
Research Site, Meissen
Research Site, München
Research Site, Offenbach
Research Site, Oschatz
Research Site, Pohlheim
Research Site, Regensburg
Research Site, Riesa
Research Site, Rodgau
Research Site, Roding
Research Site, Rosenheim
Research Site, Schlüchtern
Research Site, Schwedt
Research Site, Sinsheim
Research Site, Speyer
Research Site, Unterhaching
Research Site, Völklingen
Research Site, Wallerfing
Research Site, Wangen
Research Site, Warburg
Research Site, Wiesbaden
Research Site, Wolfsburg
Lead Sponsor
Eli Lilly and Company
INDUSTRY
AstraZeneca
INDUSTRY